Bococizumab

Jump to navigation Jump to search
Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here

WikiDoc Resources for Bococizumab

Articles

Most recent articles on Bococizumab

Most cited articles on Bococizumab

Review articles on Bococizumab

Articles on Bococizumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bococizumab

Images of Bococizumab

Photos of Bococizumab

Podcasts & MP3s on Bococizumab

Videos on Bococizumab

Evidence Based Medicine

Cochrane Collaboration on Bococizumab

Bandolier on Bococizumab

TRIP on Bococizumab

Clinical Trials

Ongoing Trials on Bococizumab at Clinical Trials.gov

Trial results on Bococizumab

Clinical Trials on Bococizumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bococizumab

NICE Guidance on Bococizumab

NHS PRODIGY Guidance

FDA on Bococizumab

CDC on Bococizumab

Books

Books on Bococizumab

News

Bococizumab in the news

Be alerted to news on Bococizumab

News trends on Bococizumab

Commentary

Blogs on Bococizumab

Definitions

Definitions of Bococizumab

Patient Resources / Community

Patient resources on Bococizumab

Discussion groups on Bococizumab

Patient Handouts on Bococizumab

Directions to Hospitals Treating Bococizumab

Risk calculators and risk factors for Bococizumab

Healthcare Provider Resources

Symptoms of Bococizumab

Causes & Risk Factors for Bococizumab

Diagnostic studies for Bococizumab

Treatment of Bococizumab

Continuing Medical Education (CME)

CME Programs on Bococizumab

International

Bococizumab en Espanol

Bococizumab en Francais

Business

Bococizumab in the Marketplace

Patents on Bococizumab

Experimental / Informatics

List of terms related to Bococizumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bococizumab (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia.

Properties

Major Trials

Phase II Trials

A 24 week, randomized, placebo-controlled, dose-ranging phase IIB trial was conducted in 354 patients to examine two different doses of bococizumab: a twice monthly dose of either 50, 100 or 150 mg; and a once monthly dose of either 200 or 300 mg. A dose reduction was made at week 6 for the twice monthly and at week 8 for the once monthly regimen in patients with LDL-C ≤25 mg/dL. The primary efficacy endpoint was the placebo-adjusted change from baseline in LDL-C at week 12. The study met its primary endpoint across all doses with a safety and tolerability profile equivalent to placebo.

Dosing regimens Mean change from baseline in LDL-C at Week 12 (placebo-adjusted) Maximum mean change from baseline in LDL-C (placebo-adjusted)
150 mg twice monthly -53.4 mg/dL -66.9 mg/dL (week 8)
300 mg once monthly -44.9 mg/dL -54.9 mg/dL (week 4)

Phase III Trials

SPIRE-HF

The SPIRE-HF trial aims to compare the effect of bococizumab in combination with a statin vs. placebo in combination with a statin on LDL-C level at 12 weeks in patients with heterozygous familial hypercholesterolemia. The trial is currently recruiting patients and is expected to be completed in January 2016.[2]

SPIRE-HR & SPIRE-LDL

The SPIRE-HR and SPIRE-LDL trial aims to compare the effect of bococizumab in combination with a statin vs. placebo in combination with a statin on LDL-C level at 12 weeks in patients with hypercholesterolemia and high cardiovascular risk. These trials are currently recruiting patients and are expected to be completed by January 2016.[2]

SPIRE-1

The SPIRE-1 trial aims to evaluate the effect of bococizumab vs. placebo (without specification regarding statin therapy) on the reduction of major cardiovascular events at 5 years, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization. The trial will only include patients with LDL-C ≥ 70 mg/dL (1.8 mmol/L) and < 100 mg/dL (2.6 mmol/L). The trial is currently recruiting patients and is expected to be completed in August 2017.[2]

SPIRE-2

The SPIRE-1 trial aims to investigate the effect of bococizumab vs. placebo (without specification regarding statin therapy) on the reduction of major cardiovascular events at 5 years, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization. The trial will only include patients with LDL-C ≥ 100 mg/dL (2.6 mmol/L) compared to the SPIRE-1 trial. The trial is currently recruiting patients and is expected to be completed in August 2017.[2]

References

  1. Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 2.2 2.3 Dadu RT, Ballantyne CM (2014). "Lipid lowering with PCSK9 inhibitors". Nat Rev Cardiol. 11 (10): 563–75. doi:10.1038/nrcardio.2014.84. PMID 24958078.


Template:WikiDoc Sources